ClinicalTrials.Veeva

Menu
L

Lillestol Research LLC | Fargo, ND

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tirzepatide
LY3298176
Metformin
Semaglutide
LY3437943
LY3857210
Retatrutide
Obicetrapib
MK-0616
fezolinetant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

32 of 117 total trials

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain (CPMP)

The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-s...

Enrolling
Chronic Low-back Pain
Diabetic Neuropathic Pain
Drug: LY3016859 ISA
Drug: Placebo Oral

A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to...

Active, not recruiting
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2

This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 dia...

Active, not recruiting
Obesity
Diabetes Mellitus, Type 2
Drug: Insuline glargine U100 (titrated)
Drug: Insuline glargine U100 (reduced)

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medi...

Enrolling
Diabetes Mellitus, Type 2
Drug: Cagrilintide
Drug: Semaglutide

This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic ste...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Drug: Placebo
Drug: Efimosfermin

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia....

Active, not recruiting
Hypercholesterolemia
Familial Hypercholesterolemia
Drug: Enlicitide Decanoate
Drug: Placebo

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction.

Invitation-only
Overweight
Obesity
Drug: Placebo
Drug: Orforglipron

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study wi...

Enrolling
Obesity
Drug: Retatrutide
Drug: Tirzepatide

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master pr...

Active, not recruiting
Overweight
Obesity
Drug: Retatrutide
Drug: Placebo

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than t...

Enrolling
Obesity
Drug: Mibavademab-Placebo
Drug: Tirzepatide-Placebo

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety an...

Active, not recruiting
Cytomegalovirus Infection
Biological: mRNA-1647
Biological: Placebo

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 recep...

Active, not recruiting
Obesity
Muscle Loss
Drug: Semaglutide
Drug: Enobosarm

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

Trial sponsors

Lilly logo
Pfizer logo
Novo Nordisk logo
Amgen logo
Merck Sharp & Dohme (MSD) logo
N
Apnimed logo
Arrowhead Pharmaceuticals logo
Astellas logo
AstraZeneca logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems